CD274 and melanoma: Recent advancements in the use of immune checkpoint inhibitors (ICIs), such as PD‐1/PD‐L1 antibodies, have generated considerable interest in their application for CRC, following their successful use in various tumors, including non—small‐cell lung cancer [34], and melanoma [35].